{"id":"tissuegene-c","safety":{"commonSideEffects":[{"rate":"null","effect":"Hepatitis"},{"rate":"null","effect":"Liver enzyme elevation"}]},"_chembl":{"chemblId":"CHEMBL3350556","moleculeType":"Small molecule","molecularWeight":"1112.80"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The HGF gene is introduced to the liver cells, where it is expressed and produces the HGF protein. This protein then stimulates the proliferation and migration of hepatocytes, promoting tissue repair and regeneration. This mechanism is particularly useful for treating liver diseases such as cirrhosis and liver failure.","oneSentence":"TissueGene-C is a gene therapy that uses a viral vector to deliver the human hepatocyte growth factor (HGF) gene to the liver, promoting tissue repair and regeneration.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:00.868Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cirrhosis"},{"name":"Liver failure"}]},"trialDetails":[{"nctId":"NCT03203330","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kolon TissueGene, Inc.","startDate":"2018-10-30","conditions":"Degenerative Osteoarthritis","enrollment":535},{"nctId":"NCT03291470","phase":"PHASE3","title":"Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kolon TissueGene, Inc.","startDate":"2021-12-09","conditions":"Degenerative Osteoarthritis","enrollment":531},{"nctId":"NCT05276011","phase":"PHASE2","title":"A Study to Determine the Safety and Efficacy of TG-C in Subjects with Symptomatic Early Hip Osteoarthritis","status":"NOT_YET_RECRUITING","sponsor":"Kolon TissueGene, Inc.","startDate":"2025-10","conditions":"Degenerative Osteoarthritis","enrollment":255},{"nctId":"NCT02341391","phase":"PHASE1","title":"Safety and Biological Efficacy Study of TisssueGene-C to Degenerative Arthritis","status":"COMPLETED","sponsor":"Kolon Life Science","startDate":"2007-02","conditions":"Degenerative Arthritis","enrollment":12},{"nctId":"NCT02072070","phase":"PHASE3","title":"Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis","status":"COMPLETED","sponsor":"Kolon Life Science","startDate":"2013-11","conditions":"Degenerative Arthritis","enrollment":163},{"nctId":"NCT00599248","phase":"PHASE1","title":"Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee","status":"COMPLETED","sponsor":"Kolon TissueGene, Inc.","startDate":"2007-01","conditions":"Osteoarthritis, Knee","enrollment":12},{"nctId":"NCT01221441","phase":"PHASE2","title":"Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee","status":"COMPLETED","sponsor":"Kolon TissueGene, Inc.","startDate":"2011-05","conditions":"Osteoarthritis, Knee","enrollment":102},{"nctId":"NCT01671072","phase":"PHASE2","title":"Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis","status":"COMPLETED","sponsor":"Kolon Life Science","startDate":"2011-07","conditions":"Degenerative Arthritis","enrollment":54},{"nctId":"NCT02341378","phase":"PHASE2","title":"Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis","status":"COMPLETED","sponsor":"Kolon Life Science","startDate":"2009-08","conditions":"Degenerative Arthritis","enrollment":28},{"nctId":"NCT01825811","phase":"PHASE2","title":"Efficacy and Safety Study of TissueGene-C Mixed With Fibrin-glue for the Patients With Degenerative Arthritis","status":"COMPLETED","sponsor":"Kolon Life Science","startDate":"2012-10","conditions":"Degenerative Arthritis","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TG-C"],"phase":"phase_3","status":"active","brandName":"TissueGene-C","genericName":"TissueGene-C","companyName":"Kolon TissueGene, Inc.","companyId":"kolon-tissuegene-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"TissueGene-C is a gene therapy that uses a viral vector to deliver the human hepatocyte growth factor (HGF) gene to the liver, promoting tissue repair and regeneration. Used for Cirrhosis, Liver failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}